European regulator EMA says that the drug Crizanlizumab should be taken off the market. The drug is supposed to help people with sickle cell disease, but research shows that the drug has no effect. The European Commission has yet to decide whether to withdraw the permit. This reports Skipr.
In sickle cell disease, insufficient oxygen is transported in the blood. Every year about fifty babies are born with this disease in the Netherlands. People with this disease are more likely to be tired, get damaged organs and experience many attacks of pain. The drug Crizanlizumab that was supposed to help with pain attacks was sold from 2020 by pharmaceutical company Novartis under the brand name Adakveo.
Placebo
A new review found that patients taking Crizanlizumab experienced just as many severe pain attacks as those taking a placebo. So the remedy did not work as intended. In some patients, the placebo, a saline solution with no effect, even worked better than the drug. These people therefore needed medical treatment at home less often. According to the EMA, the potential risks of side effects outweigh the so-called benefits.
By: National Care Guide
2023-06-06 09:27:09
#Medicine #severe #pain #attacks #due #sickle #cell #disease #work
